{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.8","upperLimit":"3.7","value":"2.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"}],"units":"Participants"}],"description":"Time from registration to the earlier of disease progression or death. Patients alive and progression-free at last follow-up were censored.\n\nProgression is defined as at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum longest diameter recorded since the baseline measurements, or the appearance of one or more new lesion(s) or unequivocal progression of existing nontarget lesions.","dispersionType":"90% Confidence Interval","groups":[{"description":"Only eligible and treated patients are included in the analysis.\n\nBAY 43-9006 was administered at a dose of 400 mg orally twice daily (total daily dose 800 mg) for eight weeks as one cycle. Patients swallowed the tablets whole with approximately 250 ml (8 oz.) of water each morning and evening (i.e., 12-hourly), with or without food. If Bay 43-9006 was taken with meals, patients were instructed to take BAY 43-9006 tosylate with a moderate to low-fat meal, as a high fat meal caused a decrease in absorption in previous studies.","id":"OG000","title":"TCC Cohort"}],"paramType":"MEDIAN","populationDescription":"Only eligible and treated patients are included in this analysis.","reportingStatus":"POSTED","timeFrame":"Assessed every cycle while on treatment; after being off-treatment, assessed every 3 months for 2 years, then every 6 months for 1 year.","title":"Progression-free Survival","type":"SECONDARY","unitOfMeasure":"Months"}